Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease
Clicks: 227
ID: 114147
2020
Airway inflammation in chronic obstructive pulmonary disease (COPD) is typically thought to be driven by Type1 immune responses, while Type2 inflammation appears to be present in definite proportions in the stable state and during exacerbations. In fact, some COPD patients showed gene expression of Type2 inflammation in the airway, and this subset was associated with the inhaled corticosteroid (ICS) response. Interestingly enough, the relationship between COPD and diseases associated with Type2 inflammation from the perspective of impaired lung development is increasingly highlighted by recent epidemiologic studies on the origin of COPD. Therefore, many researchers have shown an interest in the prevalence and the role of existent Type2 biomarkers such as sputum and blood eosinophils, exhaled nitric oxide fraction, and atopy, not only in asthma but also in COPD. Although the evidence about Type2 biomarkers in COPD is inconsistent and less robust, Type2 biomarkers have shown some potential when analyzing various clinical outcomes or therapeutic response to ICS. In this article, we review the existent and emerging Type2 biomarkers with clinically higher applicability in the management of COPD.
| Reference Key |
oishi2020journalrole
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Keiji Oishi;Kazuto Matsunaga;Toshihiro Shirai;Keita Hirai;Yasuhiro Gon;Oishi, Keiji;Matsunaga, Kazuto;Shirai, Toshihiro;Hirai, Keita;Gon, Yasuhiro; |
| Journal | journal of clinical medicine |
| Year | 2020 |
| DOI | 10.3390/jcm9082670 |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.